Project Grant R21HL189042
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $247K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Emory University $1,288,327 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on red blood cell survival in recipients with sickle cell disease. The research evaluates the impact of donor and recipient factors on transfused red blood cell (RBC) survival in sickle cell disease patients and examines mechanisms contributing to RBC clearance. The study proposes an experimental,...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1.137883 million on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the dynamics and plasticity of the hematopoietic stem cell niche. The funded work defines niche dynamics and plasticity across development, regeneration, and hematological disease; uncovers the mechanisms regulating these processes; and develops approaches to enhance...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $889,932 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer and scale production of red blood cells derived from human induced pluripotent stem cells (iPSCs) for two high-impact applications: alloantibody detection and neonatal transfusion therapy. The project addresses urgent clinical needs in two vulnerable patient populations. Sickle cell disease...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded Bloodworks $724,351 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 1, 2026, to investigate the mechanisms by which extracellular mitochondria released from traumatic brain injury sites cause endothelial cell injury and contribute to hemostatic dysfunction and coagulopathy. The research addresses a gap in understanding subcellular changes in endothelial cell injury during traumatic...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $718,991 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to determine the role of red blood cells in sepsis heterogeneity. The funded research investigates how red blood cells capture and deliver cell-free bacterial DNA to immune cells and distant organs during sepsis, a dysregulated host response to infection that remains a leading cause of death. The project...
- The National Heart, Lung, and Blood Institute awarded Emory University $797,648 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate red blood cell-bound cell-free DNA as a predictor of acute anemia in sickle cell disease. The research examines whether elevated levels of cell-free DNA released during vaso-occlusive complications in sickle cell disease bind to toll-like receptor 9 (TLR9) on red blood cells, thereby modulating red blood cell clearance...
- The National Heart, Lung, and Blood Institute awarded New York Blood Center, Inc. $703,389 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on sex dimorphism in the bone marrow niche and its effects on hematopoietic stem cell transplantation. The research investigates how sex differences in bone marrow composition and molecular signaling influence hematopoietic stem cell transplantation success in blood disease and immune disorder...
- The National Heart Lung and Blood Institute awarded North Carolina State University $698,083 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop hemostatic B-knob triggered microgels that leverage age-dependent clotting mechanisms for treating pediatric trauma-associated hemorrhage. The project addresses life-threatening bleeding in pediatric trauma patients, where hemorrhagic shock is a common cause of death. Current treatment relies on...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $655,506 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanism of antibody-mediated immune enhancement during red blood cell alloimmunization. The research examines how immunoglobulin G subclasses regulate humoral immune response to red blood cell antigens, specifically how IgG2 subclasses trigger immune enhancement through Fc gamma receptor ligation on...
- The National Heart, Lung, and Blood Institute awarded Emory University $221,270 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of microvascular rheology and transfusion in thrombosis during sepsis. The award is a project grant with period of performance through August 31, 2027. The project uses state-of-the-art microfluidics assays to characterize how red blood cell aggregation and membrane deformability affect endothelial cell...